Acrivon Therapeutics (ACRV) Assets Average (2022 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Assets Average of $118.8 million for Q1 2026, down 36.3% year-over-year from $186.5 million in Q1 2025, and down 13.62% quarter-over-quarter from $137.5 million in Q4 2025.
Acrivon Therapeutics (ACRV) Assets Average (2022 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Assets Average for 5 consecutive years, with $118.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average fell 36.3% year-over-year to $118.8 million; the TTM figure through Mar 2026 stood at $118.8 million (down 36.3% YoY), while the FY2025 annual figure was $163.2 million, down 2.55% from the prior year.
- Assets Average fell to $118.8 million in Q1 2026 per ACRV's latest filing, from $137.5 million in the prior quarter.
- Across five years, Assets Average topped out at $222.6 million in Q3 2024 and bottomed at $118.8 million in Q1 2026.
- Historically, Assets Average has averaged $162.2 million across 5 years, with a median of $160.3 million in 2023.
- Annual changes were most pronounced in 2025 — Assets Average surged 44.11% — and 2026, when it slumped 36.3%.
- Acrivon Therapeutics' Assets Average stood at $134.5 million in 2022, then increased by 7.59% to $144.7 million in 2023, then jumped by 42.13% to $205.6 million in 2024, then sank by 33.13% to $137.5 million in 2025, then declined by 13.62% to $118.8 million in 2026.
- Business Quant data shows ACRV's Assets Average at $118.8 million in Q1 2026, $137.5 million in Q4 2025, and $151.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 19.82 Bn |
| 10 | Acrivon Therapeutics | 92.88 Mn | 92.88 Mn | - | 103.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 103.46 Mn |
| Mar 31, 2026 | 118.77 Mn |
| Dec 31, 2025 | 137.51 Mn |
| Sep 30, 2025 | 151.94 Mn |
| Jun 30, 2025 | 167.47 Mn |
| Mar 31, 2025 | 186.47 Mn |
| Dec 31, 2024 | 205.64 Mn |
| Sep 30, 2024 | 222.63 Mn |
| Jun 30, 2024 | 175.55 Mn |
| Mar 31, 2024 | 129.39 Mn |
| Dec 31, 2023 | 144.68 Mn |
| Sep 30, 2023 | 155.57 Mn |
| Jun 30, 2023 | 165.12 Mn |
| Mar 31, 2023 | 175.71 Mn |
| Dec 31, 2022 | 134.47 Mn |